Gene Therapy: Rewriting the Code of Life | Investor's Almanac

Gene therapy, pioneered by scientists like William French Anderson and Michael Blaese in the 1990s, has emerged as a groundbreaking treatment for genetic diseases. By leveraging viruses like adeno-associated virus (AAV) and lentivirus to deliver healthy copies of a gene to cells, gene therapy aims to correct inherited disorders. With a Vibe score of 82, reflecting its significant cultural energy, gene therapy has sparked intense debate, particularly regarding its potential for germline editing, as seen in the controversy surrounding the work of He Jiankui. As of 2022, companies like Spark Therapeutics and Novartis have developed approved gene therapies, such as Luxturna for inherited blindness, with treatment costs reaching up to $850,000 per patient. Despite these advancements, challenges persist, including the risk of immune reactions and the high cost of treatment. As gene editing technologies like CRISPR continue to evolve, the future of gene therapy holds immense promise, with potential applications in treating complex diseases like sickle cell anemia and muscular dystrophy, but also raises critical questions about access, ethics, and the boundaries of genetic modification.